We’re delighted to share some important news about the upcoming ATC (Anatomical Therapeutic Chemical) developments for 2025!
Following the May/June 2024 vote by EPHMRA and Intellus, several new class structures have been agreed in principle.
Here’s what’s on the horizon:
- Anticorticosteroids – A new third-level class under H4 (Other Hormones) for products containing anticorticosteroids, such as those used to treat Cushing’s syndrome.
- RSV Immunoglobulins – A new fourth-level class under J6H (Specific Immunoglobulins - Antiviral) for treatments that prevent respiratory syncytial virus (RSV), like nirsevimab and palivizumab.
- COVID-19 Immunoglobulins – A fourth-level class will be introduced within J6H for COVID-19 immunoglobulins, such as casirivimab + imdevimab and cilgavimab + tixagevimab.
- RSV Vaccines – A new fourth-level class under J7E (Viral Vaccines) for respiratory syncytial virus vaccines, which were previously classified under J7E9.
- Gabapentinoids – Introducing a new third-level class under N2 (Analgesics) for gabapentinoid products, which are used predominantly for neuropathic pain.
These changes reflect the evolving nature of pharmaceutical products and ensure our classification system keeps pace with medical advancements. 
Click on the link to find out more about the 2025 ATC developments: https://lnkd.in/eFJ5m67G